Hualu Network Group
中文版
search
Home Page
About us
Our Values
Development Milestone
News
News
Products
Product List for API
Recommended API
Product List for Finished Drug
Product list for Chemicals and Intermediates
Contract Manufacturing
API and Pharmaceutical Intermediates
OTC and Generics
Investor Relation
PERIODIC REPORT
INTERIM REPORT
INVESTORS SERVICE
Contact Us
Contact Us
Investor Relation
Information transparency and trust in peers
Investor Relation
PERIODIC REPORT
INTERIM REPORT
INVESTORS SERVICE
INTERIM REPORT
Home Page
/
Investor Relation
/
INTERIM REPORT
03
2025-11
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2025
31
2025-10
Overseas Regulatory Announcement-Announcement on Having Obtained the Drug Registration Certificate and Other Relevant Information
24
2025-10
Articles of Association
Articles of Association
24
2025-10
Poll Results of the Extraordinary General Meeting
Poll Results of the Extraordinary General Meeting
24
2025-10
Renewal of Continuing Connected Transaction In Relation To Trademark Licence Agreement
Renewal of Continuing Connected Transaction In Relation To Trademark Licence Agreement
13
2025-10
Overseas Regulatory Announcement-Announcement on Bisoprolol Fumarate Tablets Having Obtained Drug Registration Certificate
10
2025-10
Announcement Notice of Board Meeting
02
2025-10
Reply Slip for the First Extraordinary General Meeting for the Year 2025
02
2025-10
Proxy Form for the First Extraordinary General Meeting for the Year 2025
02
2025-10
Notice of Extraordinary General Meeting
总条数:
87
条
＜
1
...
5
6
7
...
9
＞
跳转到:
页
跳转
Copyright © Shandong Xinhua Pharmaceutical Co., Ltd
鲁ICP备09066031号
鲁公安备案号 3703900200041
(鲁)-非经营性-2015-0068
Technical Support:CR DIGITAL
Xinhua Pharmaceutical
